Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Haas

Showing results (431-440 of 542) with videos related to

Pageof 55
Sort By:
Antimicrobial Agents and Chemotherapy|June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta, Michelle A Kendall, John G Gerber, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1992
Yeast casein kinase I homologues: an essential gene pairL C Robinson, E J Hubbard, P R Graves, et al.
The Journal of Infectious Diseases|April 21, 2010
African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapyJeffrey A Canter, Gregory K Robbins, Doug Selph, et al.
Clinical Pharmacology and Therapeutics|February 25, 2014
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 updateM A Martin, J M Hoffman, R R Freimuth, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2003
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group studyDavid W Haas, Hulin Wu, Haihong Li, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Estimating optimal therapeutic drug levels of anti-tuberculosis medications based on treatment safety and effectivenessGustavo Amorim, David W Haas, Marcelo Cordeiro-Santos, et al.
Pneumologie (Stuttgart, Germany)|May 12, 2011
[New recommendations for contact tracing in tuberculosis. German Central Committee against Tuberculosis]R Diel, G Loytved, A Nienhaus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 17, 2006
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicityMarylyn D Ritchie, David W Haas, Alison A Motsinger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Pageof 55

Showing results (431-440 of 542) with videos related to

Sort By:
Pageof 55
Antimicrobial Agents and Chemotherapy|June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta, Michelle A Kendall, John G Gerber, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1992
Yeast casein kinase I homologues: an essential gene pairL C Robinson, E J Hubbard, P R Graves, et al.
The Journal of Infectious Diseases|April 21, 2010
African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapyJeffrey A Canter, Gregory K Robbins, Doug Selph, et al.
Clinical Pharmacology and Therapeutics|February 25, 2014
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 updateM A Martin, J M Hoffman, R R Freimuth, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2003
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group studyDavid W Haas, Hulin Wu, Haihong Li, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Estimating optimal therapeutic drug levels of anti-tuberculosis medications based on treatment safety and effectivenessGustavo Amorim, David W Haas, Marcelo Cordeiro-Santos, et al.
Pneumologie (Stuttgart, Germany)|May 12, 2011
[New recommendations for contact tracing in tuberculosis. German Central Committee against Tuberculosis]R Diel, G Loytved, A Nienhaus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 17, 2006
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicityMarylyn D Ritchie, David W Haas, Alison A Motsinger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Pageof 55